Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bièche I, Decaudin D, Marangoni E. Romanelli A, et al. Among authors: assayag f. Mol Cancer Ther. 2012 Dec;11(12):2693-703. doi: 10.1158/1535-7163.MCT-12-0441-T. Epub 2012 Sep 25. Mol Cancer Ther. 2012. PMID: 23012245
A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF. Marangoni E, et al. Among authors: assayag f. Clin Cancer Res. 2007 Jul 1;13(13):3989-98. doi: 10.1158/1078-0432.CCR-07-0078. Clin Cancer Res. 2007. PMID: 17606733
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, Assayag F, Bourgeois Y, Poupon MF, Decaudin D. Némati F, et al. Among authors: assayag f. Anticancer Drugs. 2010 Jan;21(1):25-32. doi: 10.1097/CAD.0b013e3283300a29. Anticancer Drugs. 2010. PMID: 19823076
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.
de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E. de Plater L, et al. Among authors: assayag f. Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877358 Free PMC article.
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Cottu P, et al. Among authors: assayag f. Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16. Breast Cancer Res Treat. 2012. PMID: 22002565
33 results